QCG
RVMD icon

Quadrant Capital Group’s Revolution Medicines RVMD Stock Holding History

Quadrant Capital Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Hold
1,312
– – ﹤0.01% 1412
2025
Q4 		$105K Buy
1,312
+995
+314% +$65.2K ﹤0.01% 1479
2025
Q3 		$14.8K Buy
+317
New +$12.4K ﹤0.01% 2044
2025
Q2 		– Sell
-322
Closed -$11.4K – 2350
2025
Q1 		$11.4K Sell
322
-19
-6% -$771 ﹤0.01% 2194
2024
Q4 		$14.9K Hold
341
– – ﹤0.01% 1998
2024
Q3 		$15.5K Sell
341
-37
-10% -$1.61K ﹤0.01% 1996
2024
Q2 		$14.7K Hold
378
– – ﹤0.01% 1982
2024
Q1 		$12.2K Hold
378
– – ﹤0.01% 2032
2023
Q4 		$10.8K Hold
378
– – ﹤0.01% 2039
2023
Q3 		$10.5K Hold
378
– – ﹤0.01% 1974
2023
Q2 		$10.1K Hold
378
– – ﹤0.01% 1988
2023
Q1 		$8.19K Buy
+378
New +$9.31K ﹤0.01% 2108
2022
Q4 		– Sell
-73
Closed -$1K – 2835
2022
Q3 		$1K Buy
+73
New +$1.6K ﹤0.01% 2553

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Quadrant Capital Group's RVMD Position: Q1 2026 in Review

Quadrant Capital Group held its Revolution Medicines (RVMD) position steady in Q1 2026 at 1,312 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Quadrant Capital Group first reported a position in RVMD in Q3 2022 and has held it in 13 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Quadrant Capital Group held 1,312 shares of Revolution Medicines worth $128K as of Q1 2026.
  • Quadrant Capital Group left its Revolution Medicines share count unchanged in Q1 2026.
  • Revolution Medicines made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1412 holding.
  • Quadrant Capital Group first reported a position in Revolution Medicines in Q3 2022 and has held it in 13 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.